Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: An updated systematic review and meta-analysis with focus on an Asian subpopulation.

ABSTRACT:

Aims

This updated meta-analysis investigates the efficacy and safety of combining sodium-glucose cotransporter 2 inhibitors (SGLT2is) with dipeptidyl peptidase-4 inhibitors (DPP4is) in treating type 2 diabetes (T2D), especially in Asian subpopulations.

Materials and methods

A systematic review was conducted on randomized controlled trials (RCTs) published through January 2024 that compared SGLT2i/DPP4i combination therapy with DPP4i or SGLT2i monotherapy. The primary outcome was haemoglobin A1c (HbA1c) changes. Subgroup analyses were conducted based on the baseline HbA1c level (using 8.0%-8.5% as the cut-off) and racial groups (Asian vs. non-Asian).

Results

This analysis included 17 RCTs with 7588 participants. Compared to DPP4i, the SGLT2i/DPP4i combination significa

SUBMITTER: Kim MJ 

PROVIDER: S-EPMC12326950 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature